Artdoc-B (02251) has announced its interim results for the 2026 fiscal year, with revenue declining 19.6% year-on-year to RMB 67.29 million and a loss attributable to parent company shareholders expanding by 2,820% to RMB 48.85 million. The basic loss per share stood at RMB 0.48.

The widened loss during the period was primarily attributed to several factors, including a decrease in revenue resulting from the implementation of stricter agent selection policies and tightened credit terms, as well as increased investment in research and development and clinical trials. The company intensified its efforts in developing the "Wanyu" medical large model, AI Agent solutions for various product lines, computing power, and medical data governance, alongside advancing multi-center clinical studies, medical device registrations, and compliant commercialization, which led to higher R&D and clinical expenditures.

Additionally, the PBM-AI myopia prevention and control business remains in its early scaling and cultivation phase. While the number of partner stores, users, and model invocation volumes grew, increased spending on marketing, medical services, store deployment, operations, and consumer-facing eye health marketing and operations has yet to translate into meaningful revenue contributions or economies of scale. Fluctuations in foreign exchange rates also had a certain impact on the group's financial position.

During the reporting period, the group leveraged its self-developed Wanyu large model to empower its mid-and back-office functions, driving cost reduction and operational efficiency gains, which helped partially offset some of the aforementioned pressures.